Valeritas — Investor Presentation (November 2016)
41 slides from Valeritas's investor presentation, Nov 17, 2016
Slide 1: Investor Presentation, November 2016
Exhibit 99.1 D E LTimberlake, Investor OTCQB: John November I VPresentation VLRX E2016 R I NPresident G Q U A&L ICEO TYOFLIFE
Slide 2: Forward-Looking Statements
Forward stated “Valeritas,” This future reasonable “would”, “expect,” except Our reliance V-Go our obsolete risks components successful 2and inability materially operations estimates, presentation related to in events toon achieve or this Looking the ““plan” commercialization assumptions “will,” V-G
Slide 3: Valeritas Investment Highlights
Valeritas Significantly ~$20M > Substantial Addressing Established commercial primarily cost Robust 3Capital-efficient 10 neutral million clinical revenue with distributed growth needs reimbursement vs. and V-Go’s de-risked V-Go® insulin data: & Medicare commercial of 35% opportunities dispensed 4.6
Slide 4: Company Summary
Investment Company Focused Significantly Commercial New Gross ~35% 4Company’s device Plan Margin GMand Incorporated has showing on Summary intent focused Operations capital-efficient reduced Transitioned ~$20M Leverage isearly to investors, cash revenue raise Market atresults Inflection use tocapita
Slide 5: Proven Leadership Team and Board
The Valeritas Proven Years Industry John President Erick Chief Matt SVP Geoffrey EVP Majority Luke CRG 5Investment Commercial Manufacturing, Timberlake Nguyen Düster Healthcare Lucera Financial ofTrack Experience /independent Jenkins & Valeritas Mgt. Chief Brian 21 Leadership 21 Record Officer //Ave
Slide 6: V-Go: The Only FDA-cleared Disposable Insulin Delivery Device
V-Go® The Only Specifically Small, Convenient 6Reimbursed Ideal FDA-cleared discreet, Disposable Insulin drug-like designed at the wearable, Delivery pharmacy single-use, Insulin distribution to address disposable Device Delivery – fully where unmet model For disposable device: and patients Patients
Slide 7: V-Go Simple, Wearable Device
V-Go® Preset On-demand Activate 71Step Step Bolus basal Delivery Bolus Robust :2Bolus Combines Ready IP Bolus Delivery insulin rates Bolus Button with Ready Step of Button 70 for Button Simplicity insulin Button mealtime patents 3delivered Deliver issuedand coverage Physiologic and at Insulin 51 ape
Slide 8: Addresses the Physiologic Need and Market Opportunity
Addresses The Physiologic 465IProgrammable 4.6 Opportunity 23B 1or 1.4 0N Insulin A1C Type at Regimens (1) WAC (2) Figures 8Grabner 23;5:471-9. ntensive asal onphysiologic $16 Premix >95% A1C Based Holman Annual Basal 4.6 Goal 2+1 price Billion Patients (millions) Goal approximate. Million of M, The
Slide 9: Patient Simplicity and Discretion
Complexity 72% they V—G Simplicity V-Go or Data 92,000 when do Patients from allows diabetes onot ® they U.S. Ease-of-use Sinject and O patients have prescribed patients LV Roper Lack insulin aES snack to of Diabetes UDiscretion (n=2,104 easily ?Discretion N away 3in Mshots/day public E and from Pat
Slide 10: U.S. Prescribers and Sales Expansion
14,000 U.S. Prescribers*** Prescribers 1,000** 0% Field Significant for *Growth Representatives 10 Future Inside High Sales generate Annual SymphonyCurrent Valeritas Figures Number These isV-Go® Sales Insulin Growth Potential Professionals Supported Insulinof14,000 Estimated Sales ofVolume approxima
Slide 11: Where V-Go Is Sold: Pharmacy Distribution
V-Go® Where V-Go ~90% Through Durable Sold •Equipment patients Traditional 11 insurance Enhanced atType for Distribution Patients Pharmacy is who Medical Wholesalers Type Accessible 1Co-pay Patient frequent Pump 2with Diabetes / Convenience Retail at Maker Type at Pharmacy pharmacy Retail Outlets Ty
Slide 12: Established Reimbursement and Access
Established 70%+ < of Not or Access V-Go Medical Under 164 Insurance Diabetes Over TRICARE *All 12Commercial 30% Lives Restricted Access Covered M 90% Covered Commercial Exception Pharmacy <ofV-Go 70%+ 40% Prevalence Pharmacy Lives of & figures Reimbursement Formulary Not V-Go State Pharmacy Covered
Slide 13: Cost Neutral to Payors vs. Basal/Bolus Therapy
Established Basal/Bolus Neutral (~$18/day) V-Go® $31 $73 co-pay *What and 13 Health $31aNeutral $62 co-pay Therapy is Cost $11 or Payor Cost-effective $84 Research between Reimbursement Pen $31 toco-pay Pays Cost Payors Therapy or $53 Regimens* to (Net &co-pay1 Patients Education $31 for of both Reb
Slide 14: Extensive Clinical Data Supports Adoption
Strong Statistically Improvements Improved Papers Clinical patients ~750* Lowered (Prescribed 37 14 and studied Total Demonstrated *Excludes Meetings Medical (1) at (6)73rd Quality Rosenfeld Lajara Extensive /Significant Administered)(1-6) in Daily Scientific R169 etCR, A1C(1-6) Cost al. V-Goof Life
Slide 15: Robust Clinical Data Validates V-Go
Robust SIMPLE(1) Basal 9BL: in A1C -1.2 Months -1.0 -1.5 8.7% Change -2.0 -1.9 -2.4 BL= (1) (2) (3) Cohort Clinical -1.2 ~7 BL: -1.6 -1.8 -2.0 Clinically DA(2) Grunberger BaselineMonths Vs. Lajara9.5% Data Relevant Omer A,G, R,MDIUMASS(3) BL: Validates 3 All Months etDavidson et(-0.5%) al. al. 10.7%
Slide 16: V-Go Is Cost-Effective vs. MDI
V-Go® †V-Go $217.16 $250 Month Per Cost Pharmacy $100 Direct MDI $0 †P-value Insulin prescribed therapy Lajara 16P=0.013 inreduction V-Go Reduced Per R, A1C costs is costs. calculated Davidson a1% $50 daily More $200 include All $150 Direct insulin pricing Cost-Effective JA, using $118.84 both Pharm
Slide 17: Extensive V-Go Experience
Extensive V-Go® 6810 14 Million V-Go Source: 17 product Patientquality Million adherence Symphony &Experience demonstrated With persistency Health Proven Solutions better with most > Quality (Retail than 10M and devices Type Mail dispensed 2Order). regimens to patients (injections or pills)
Slide 18: Focused, Capital-Efficient Commercial Strategy
Focused Before Capital Short Reactionary Approach/Message Single Targeting Inconsistent 18 ROI Channel Today uncertainty and Consistent, measurement Long Marketing Patient Service Capital-Efficient (rep/doctor) Term Capital Message Clear Model Device-like Consistent plan Strategic Patient access Ser
Slide 19: Focused Target Prescribers and Multichannel Marketing
Current Focused, Target Insulin Volume Instead Prescribers minutes doctor’s Activate Patients Seek for Estimated growth Greater Execute Support Prescriber & HCP 19 Patient V-Go –&High Healthcare changed in of Ask revenue Sales doctors at to for < office Increase Integrated S&M 2016 ~15 8% 50% Market
Slide 20: Refined Targeting Model
Actual Current Target Rep Access Academic “no-rep Reimbursement Rapid Physicians Top INSULIN BLINDED Dr Source: 20 9742~30 10 12 15 16 18 19 20 27 28 29 31 32 34 35 37 38 39 40 41 42 43 44 45 46 47 49 8653150 11 13 14 17 21 22 23 24 25 26 30 33 36 48 51 52 56 83 93 104 Decile relationships UNKNOWN E
Slide 21: Expanding Territory Coverage
Ability Target TOTAL_INSULIN_ BLINDED Dr 1Moving increase I. II. in current III. Splitting IV. Current Territories 2017 U.S. 14,000 0% Coverage NRx: Prescribers* 21 NRx Increase Geographic Gradually 86531Add 11 13 14 17 21 22 23 24 25 26 30 33 36 48 51 52 56 83 93 104 Increase High 10 Sales New 10 9
Slide 22: Integrated HCP and Patient Activation
Integrated and Patient Activation Desiring Reach on HCP desire Direct Banner Search In-Office In-Pharmacy Highly with •opportunity KOL: MDI HCP: 22 E-Mail Benefit Education Co-Pay Insurance Pharmacy V-Go Educated focused about (multiple Health Key to Mail patients Engine Interested & targeted Advert
Slide 23: Patient Activation Strategy
Drive advocacy Display V-Go (enhanced) Direct starter Enhanced Rx In-office CONVERSIONgo-vgo.com Ambassadors Patient 23 Edge Life Patients mail kit Activation V-Go Demo advertising Pharmacy material Paid Context Email Customer units to search Ask Strategy media for / SEO Care and Stay on V-Go®
Slide 24: Focused, Scalable Business Model
Focused Scalable Model Business Short CommerTerm Collaborat and Launch TIME Capital V-Go® Long Efficient Term PrefillGrowth Strategy
Slide 25: V-Go Product Line Extensions
V-Go® Current Filled insulin EZ •Commercially to (1) (2) 25Approved Could make Assumes Product Fillby from •V-Go® Line be product treatment Permits patient used currently invial V-Go’s Extension E.U. available LinkTM(2) as Provides by using tracking adjustments diagnostic •transferring and Increases
Slide 26: Valeritas Financial Summary
Valeritas: Poised Annual 34% 2016 $18.1 $13.5 the $14.7 118% Q3’16 $6.2 ~ $0.6 2012 2Q16 Revenue Gross Operating Net Cash The 2664Sales Loss Company Reduction reps sales ~2013 Burn $15.5 Financial with Representatives YTD Margin Significant $[VALUE] for Revenue ($ $4.9 $9.2 reps Financial ~ Expenses
Slide 27: Comparative Company Profile
Comparative ?Striving margin (millions) Company Gross DXCM1 Revenue Sales SGA GM EV “DXCM” “SGA” The *Source: 27 Valeritas Number (M) number should (%) (M) Reps (M) Margin profile means SEC $226 to -405% ?DXCM2 $21 refers to should $2 at of At has Change 40* be immediately ~$60M achieve Sales Form D
Slide 28: Financial and Stock Highlights
Financial Common Shares Share Market LTM Total Largest Cash ADTV (4,330 28 & Burn Revenue EBITDA($34.7M) Debt Price after on –Cap Shareholder Short-Term 90 Highlights Stock a$57.4M (12 (as fully S1 (as Days $19.6M Mo declared of of Outstanding diluted (as 11/09/2016) 11/09/2016) &($52.2 Investments
Slide 29: Investment Conclusion
Investment Compelling diabetes Commercial –Gross Company 29Positive ~35%Margin GM market Transitioned intends early Conclusion opportunity Operations onLeverage results ~$20M with to raise thedemonstrating to revenue at creating potential acapital Inflection Medical with sufficient ato new Device ge
Slide 30: V-Go Clinical Summary
D E L I Clinical V-Go® VERIN Summary GQUALITYOFLIFE
Slide 31: Better Glycemic Control Improves Health Outcomes
Better43% Significant Each reduces Deaths 21% Microvascular Complications 37% Stratton 31 14% 1% Glycemic from risk IMreduction Adverse et for Diabetes al. Peripheral Disease Control BMJ. inHealth mean Heart 2000;321:405-412. Improves Vascular Effects A1C AttacksInfluenced and ExtendsbyLives Poor Gl
Slide 32: Large Scale Study Validates V-Go Candidates
Large 20% Goal 30% 35% atients 25% P of Percent <7% 0% 5% A1C *2011 3220% Insulin at 32.7% Range >7% are Database Scale 26.5% 80% On Insulin: V-Go 15% or10% Study of ClinicoEconomics<8% Candidates analysis 20.4% Patients Basal, >8% Validates and20.4% Basal of Currently or 27,897 <9% 80% plus Outcome
Slide 33: Many Type 2 Patients Require Basal and Bolus Insulin
Many Mealtime 250 (1) 50 Type (mg/dL) 100 Glucose Time 82% Adapted Holman 33 ofPatients 12PM200 AMElevated 2of 06Plasma / Prandial NormalHyperglycemia Diabetes Glucose 150 Patients Day RR Levels from: et 6PMwith Basal al. Type Levels Riddle. Basal with N 12AM Engl Type2J 2Diabetes Diabetes 6AM Med.
Slide 34: Robust A1C Reductions
Robust SIMPLE(1) Basal 9BL: in A1C -1.2 Months -1.0 -1.5 8.7% Change -2.0 -1.9 (3) (5) (8) Cohort Patients N’s 34 Clinical -1.2 ~7 BL: -1.6 -1.8 Clinically -2.4 BL= (1) -2.0 Grunberger Omer Sandberg Baseline =SIMPLE- naiveDA(2) etMonths Sutton A, Vs. 9.5% Relevant M,toData al. G, D, et 59,MDI UMASS(
Slide 35: Switching to V-Go Reduces Insulin Dose
Switching Diabetes SIMPLE(1) Baseline Insulin in -22% -Change % (1) -46% (2) (4) (6) Sessions *Change 35 41% -18% Grunberger Rosenfeld Lajara -23% -13% -28% 62 of Diabetes inR, tothe basal America(2) UV-Go® Davidson et CR, TDD ADA; G, al.component et Diabetes 78 al. Demonstrated June U JA, Poster En
Slide 36: V-Go Reduces A1C and Insulin Use
V-Go® Key 140 120 (units) Change 100—2.4 119—55U 10.0 80 60 TDD Insulin 40 20 0Change †Pre N=14 (1) 11.0 10.7 Benefit =64† 6.0V-Go P=0.01, Omer, 36 Significantly A1C A. 46%(1)(%) 8.0 7.0 -55 Average et toV-Go 8.3* -2.4 Based Onal. Both Patients 9.0 Reduces onUInsulin *P=0.001 Duration Pre Poster 88
Slide 37: V-Go vs. MDI Glycemic Control
V-Go® Glycemic Better 10.0 90 80 9.5 9.0 8.4* Control Demonstrates P<0.0001 Control weeks 27 withvsLess 708.1* 78* Multiple Significant Insulin Daily vsImprovements MDI Injections (MDI) In (%) 60 7.7*8.5 A1C V-Go 50 7.5 8.0MDI P=0.02(U/day)at 40 7.6* 6.5 7.0 37 R,56 Baseline V-Go V-Go: week Lajara T
Slide 38: V-Go Improved Control Across Insulin Dose Groups
V-Go® After Patients 143 (U/day) TDD Insulin V-Go < -1.7* Baseline N= †P<0.05 Lajara 38100 66 <62 6V-Go Improved 100 U/day patients R, 54† Months Appropriate A1C on 67* compared 9.3% @6 Baseline Nikkel U/day <Change V-Go at in mos. 100 Baseline <?of A1C 100 C. atU V-Go Using Baseline to TDD JFor Con
Slide 39: V-Go in Insulin-Naive Patients
Potential Significant Reduction 01On Insulin Dose of 100 80 20V-Go -3 A1C TDD Naïve -0.5 in for at Daily(U/day) Total Mean LSM 20 -3.5 60 40 *p<0.001 N= 39 24, on -1 A1C 27 -3.0* 54** -2.5 -3.4*V-Go Utilization V-Go Patients Weeks -1.5 Baseline totobe Change compared A1C =14 Could -2 First-Line Week
Slide 40: Patients Rate V-Go Convenience and Quality of Life
Patients Convenience(1) 90% 70% 80% Very 60% 50% Respondents 30% Survey 20% 10% 0% Prior Therapy How mentally (1) 40 0% Note: 70% 20% 53% Convenient 44% 29% 28% do V-Go Survey Rate you Data Therapy on Convenient Good 27% Prior afeel Patients40% the on typical 20% 10% Quality File V-Go physically Con
Slide 41: Thank You
D E L Iyou Thank VERINGQUALITYOFLIFE
Valeritas Holdings — Investor Presentation (November 2016) on 6ix